Facebook Tracking Image

National Comprehensive Cancer Network

About NCCN

NCCN Flash Updates: NCCN Guidelines® and NCCN Compendium® Updated for Non-Small Cell Lung Cancer (NSCLC)

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs and Biologics Compendium (NCCN Compendium®) for Non-Small Cell Lung Cancer (NSCLC). These NCCN Guidelines® are currently available as Version 2.2020.

  • Advanced or Metastatic Disease
    • Sensitizing EGFR Mutation Positive (NSCL-19)
      • The following regimens added for the first-line treatment of patients with metastatic NSCLC and an EGFR mutation.
        • Erlotinib + ramucirumab as an "other recommended" treatment option as a category 2A.
        • Erlotinib + bevacizumab as a "useful in certain circumstances" treatment option as a category 2B.
    • PD-L1 Expression ≥1% (NSCL-28, NSCL-29)
      • The following treatment options added for patients with metastatic NSCLC, PD-L1 ≥1%, and PS 0-2.
        • Carboplatin + albumin-bound paclitaxel + atezolizumab as an "other recommended" treatment option as a category 2A. (NSCL-28)
        • Nivolumab + ipilimumab as a "useful in certain circumstances" treatment option as a category 2A. (NSCL-28, NSCL-29)
    • Adenocarcinoma, Large Cell, NSCLC NOS and EGFR, ALK, ROS1, and BRAF negative, PD-L1 <1% (NSCL-30)
      • Continuation maintenance
        • Atezolizumab added, if atezolizumab/carboplatin/albumin-bound paclitaxel given.
  • Systemic Therapy for Advanced or Metastatic Disease
    • Initial Systemic Therapy Option (NSCL-J 2 of 4)
      • The following treatment options added for patients with metastatic adenocarcinoma, large cell, NSCLC NOS, PD-L1 <1%, and PS 0-1.
        • Carboplatin + albumin-bound paclitaxel + atezolizumab as an "other recommended" treatment option as a category 2A.
        • Nivolumab + ipilimumab as an "other recommended" treatment option as a category 2A.
    • Initial Systemic Therapy Options (NSCL-J 3 of 4)
      • The following treatment option added for patients with metastatic squamous cell carcinoma, PD-L1 <1%, and PS 0-1.
        • Nivolumab + ipilimumab as an "other recommended" treatment option as a category 2A.


Previous updates to the NCCN Guidelines for Non-Small Cell Lung Cancer can be found in the UPDATES section of the current version.

 

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Please note: The NCCN Third Party Content FTP site: ftp://ftp1.nccn.org/ThirdPartyContent/ has been updated. Licensees are solely responsible for obtaining permission from such third party to use any such Third Party Content in the Permitted Works.

Access information on permissions and licensing of NCCN Content

Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.